- (PLX AI) - Lundbeck shares are likely to gain today after the company reported positive results in Alzheimer's agitation with its drug Rexulti in a phase 3 trial, analysts said.
- • Results for treatment of agitation in patients with Alzheimer's dementia showed that patients treated with brexpiprazole (Rexulti) had a statistically significantly greater reduction in agitation compared to placebo
- • Based on this outcome Lundbeck and Otsuka are planning a regulatory filing to the FDA later in 2022
- • Currently there are no FDA approved pharmacological treatments for agitation in Alzheimer's dementia, with a significant unmet medical need that will likely only increase, analysts said
- • This is likely to lead to a boost in growth for Rexulti after the full data has been published, and improves Lundbeck's sales and earnings outlook for 2023-2028, analysts at SEB said
- • We expect a significant positive share price reaction: SEB
© 2022 PLX AI
